Skip to main content
Premium Trial:

Request an Annual Quote

OpGen to Execute 1-for-25 Reverse Stock Split

NEW YORK (GenomeWeb) – OpGen announced after the close of the market Wednesday that it will effect a 1-for-25 reverse stock split of its common shares.

The company said that it anticipates its common stock to trade on a split-adjusted basis under ticker symbol "OPGN" at the start of trading on Jan. 19. Also, the warrants to purchase shares of OpGen's common stock issued as part of its initial public offering will trade on a split-adjusted basis under ticker symbol "OPGNW" at the start of trading on the same day.

The reverse stock split is being undertaken to increase OpGen's share price so that the company can continue listing its stock on the Nasdaq. In June, the exchange warned the firm that it did not meet a listing requirement calling for a minimum bid price of $1 per share. Last month, OpGen said it would meet with a Nasdaq panel in an effort to continue listing on the exchange. In May, Nasdaq also warned the firm that it fell short of a listing requirement calling for at least $2.5 million in stockholders' equity.

An oral hearing with the panel is scheduled for Feb. 8.

As a result of the reverse split, the number of OpGen's shares will be reduced to about 2.3 million shares from about 56.5 million shares. The number of shares authorized for issuance by the company will also be reduced, to 50 million from 200 million.

OpGen's shares were down more than 3 percent in early morning trading on Thursday at $.1601.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.